$TARS News

Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89

Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target

Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc., - M&A Call - Slideshow

Tarsus Acquires iRenix Medical And Late-Stage Asset IRX-101 For ~$75M

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Watching Tarsus Pharmaceuticals; Shares Move Lower, Culper Research Issues Report On Co Titled "XDEMVY’s Charitable Foundation Scheme, Specialty Pharmacy Gimmicks, and Make-Believe TAM"; Holds A Short Position

Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work

A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains

Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?

Tarsus Pharmaceuticals Q1 Earnings Call Highlights